<DOC>
	<DOCNO>NCT02689245</DOCNO>
	<brief_summary>Data stool microbiome collect chronic hepatitis B subject ( pre cirrhotic , compensate , decompensated reactivation ) . All patient Hepatitis B reactivation recruit randomized two arm . Group 1 Tenofovir Group 2 Tenofovir FMT ( Fecal Microbiota Transplant ) . Tenofovir would give 300 mg daily FMT NJ ( Naso-Jejunal ) tube 7 day .</brief_summary>
	<brief_title>Randomized Controlled Trial Comparing Efficacy Safety FMT Hepatitis B Reactivation Leads Acute Chronic Liver Failure .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Reactivation Chronic Hepatitis B Virus lead Acute Chronic Liver Failure ( MELD ( Model End Stage liver Disease ) &gt; 18 year . 2 . 1875 yr male female 3 . Chronic Hepatitis B patient ( precirrhotic , compensate , decompensated ) . 4 . Healthy adult family member patient take control . Acute Chronic Liver Failure due cause Alcohol , Hepatitis A Virus , Hepatitis E Virus , HSV ( Herpes Simplex Virus ) , CMV ( Cytomegalovirus ) , EBV ( EpsteinBarr Virus ) hepatotropic virus , Drugs , CAM . Active gastrointestinal bleeding Intracranial bleeding Multiorgan failure ( &gt; 2 ) mechanical ventilation SOFA score &gt; 2 On high inotropic support Paralytic ileus Pregnancy Hepatocellular Carcinoma Antibiotic , probiotic within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>